Evommune EVMN
NYSE EVMN
$8.64 +0.80 (+10.14%)
As of: Nov 11, 2026 · 3:59 PM EST

Evommune (EVMN) Net Margin (2025)

Updated

Evommune's Net Margin was -529.77% in FY2025, up 424.63 percentage points from -954.40% in FY2024.

Analysis

Evommune (EVMN) Net Margin (2025) Analysis & Trends

  • Per Business Quant data, Net Margin in earlier years was -954.40% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 26.44%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 0.83%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 24.24%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 28.01%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 20.69%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 37.28%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 29.27%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 19.55%
10 Evommune 285.17 Mn -352.34 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -124.75%
Mar 31, 2025 -485.23%
API Access

Evommune Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=EVMN&period=max&api_key=YOUR_API_KEY